Hyperion DeFi announced that its Board of Directors has appointed Hyunsu Jung as CEO, effective immediately. "I am honored to step into the CEO role at Hyperion DeFi during this important phase for the digital asset industry," said Jung. "Our focus is on building a leading Hyperliquid-native DeFi company that supports global adoption, monetizes growth through disciplined on-chain strategies, and provides shareholders with meaningful exposure to the expansion of the Hyperliquid ecosystem. As the market continues to prioritize fundamentals and sustainable revenue models, we believe Hyperion DeFi is well positioned to differentiate itself in 2026 and beyond." In addition to the CEO appointment, Robert Rubenstein will be joining as General Counsel, effective January 12, 2026.
Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
